首页 > 市场调查报告书 > 製药

神经疾病

痴呆症药物市场:按药物类别、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030

市场调查报告书

商品编码

1110217

痴呆症药物市场:按药物类别、分销渠道、地区 - 规模、份额、前景、机会分析，2022-2030

Dementia Drugs Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月22日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

简介目录

痴呆症是一种影响大脑功能并降低记忆力和思维能力的疾病。阿尔茨海默病是 65 岁以上人群中最常见和最大的痴呆形式（>60%）。痴呆症是由多种主要或次要影响大脑的疾病和损伤引起的，例如阿尔茨海默病和中风。它影响记忆、思维、定向、理解、算术、学习能力、语言和判断力。认知功能受损通常伴随着情绪、情绪控制、行为或动机的变化，但有时也伴随着这些变化。痴呆症的主要原因是由于基因突变导致神经细胞中一种称为BETA-淀粉样蛋白的蛋白质的积累。痴呆症是一种无法治癒的疾病，但在所有情况下都会给予对症治疗。正在开发以 BETA-淀粉样蛋白在痴呆中的作用为中心的治疗方法。

市场动态

监管机构不断增加的产品批准是痴呆症治疗市场增长的主要驱动力。例如，2021 年 6 月 24 日，製药公司礼来公司（Eli Lilly & Co.）宣布礼来公司（Lilly & Co.）针对阿尔茨海默病（AD）的研究性抗体治疗药物多那奈（donanemab）被美国食品药品监督管理局（Food and Drug Administration）（ FDA ）批准为突破性疗法宣布已被任命。突破性疗法认定表明，与 FDA 批准的疗法相比，用于治疗严重疾病的药物可能在临床重要终点方面表现出显着改善。它旨在在有初步临床证据时加快开发和审查。阿尔茨海默病是最常见的痴呆症，占病例的 60-80%。

本研究的主要特点

本报告对全球痴呆治疗市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。
解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
基于公司亮点、产品组合、关键亮点、财务业绩和战略等参数的全球痴呆治疗市场主要参与者的概况。
本次调查涵盖的主要公司包括卫材、杨森製药、百健製药、Forest Laboratories, Inc.、礼来公司、诺华製药、赛诺菲、阿斯利康、F Hoffmann-La罗氏、默克公司、Valeant Pharmaceutical International、辉瑞公司和梯瓦製药工业有限公司。
本报告中的见解将使营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
全球痴呆症治疗市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
它将通过用于分析全球痴呆症药物市场的各种战略矩阵促进决策制定。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

举报内容
- 市场定义和范围
执行摘要
- 市场快照:按药物类别
- 市场快照:按分销渠道
- 市场概况:按地区划分
连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

市场动态
- 驱动程序
- 约束因素
- 市场机会
主要亮点
市场趋势
PEST 分析
政府和非政府举措
流行病学

第 4 章全球痴呆症药物市场 - 冠状病毒 (COVID-19) 大流行的影响

整体影响
政府举措
COVID-19 对市场的影响

第 5 章全球痴呆药物市场，按药物类别，2017-2030 年

MAO抑製剂
胆碱酯□抑製剂
谷氨酸抑製剂

第 6 章全球痴呆症药物市场:按分销渠道，2017-2030 年

医院药房
零售药房
其他

第 7 章。全球痴呆药物市场:按地区划分，2017-2030 年

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
意大利
法国
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
东盟
澳大利亚
韩国
其他亚太地区
中东
海合会
以色列
其他中东
非洲
北非
中非
南非

第 8 章竞争格局

热图分析
市场份额分析
公司简介
- Eisai, Inc.
- Janssen Pharmaceuticals, Inc.
- Biogen Pharmaceuticals
- Forest Laboratories, Inc.
- Eli Lilly and Company
- Novartis AG
- Sanofi S.A.
- AstraZeneca GmbH
- F. Hoffmann-La Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.

第九章章节

调查方法介绍
关于出版商

简介目录

Product Code: CMI1664

Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer's disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Dementia results from a variety of diseases and injuries that primarily or secondarily affect the brain, such as Alzheimer's disease or stroke. It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The impairment in cognitive function is commonly accompanied, and occasionally preceded, by changes in mood, emotional control, behavior, or motivation. Accumulation of a protein called beta amyloid in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop therapies centered on the role of beta-amyloid in dementia.

Market Dynamics

Increasing product approval by regulatory authorities is the major driving factor for growth of the dementia drugs market. For instance, on June 24, 2021, Eli Lilly and Company, a pharmaceutical company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available therapies that have received full FDA approval. Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases.

Key features of the study:

This report provides an in-depth analysis of the global dementia drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Detailed Segmentation:

Global Dementia Drugs Market, By Drug Class:
- MAO Inhibitors
- Cholinesterase Inhibitors
- Glutamate Inhibitor
Global Dementia Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Dementia Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Eisai, Inc. *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Janssen Pharmaceuticals, Inc.
- Biogen Pharmaceuticals
- Forest Laboratories, Inc.
- Eli Lilly and Company
- Novartis AG
- Sanofi S.A.
- AstraZeneca GmbH
- Hoffmann-La Roche
- Merck & Co., Inc.
- Valeant Pharmaceutical International
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Key Highlights
Market Trends
PEST Analysis
Government & Non-Government Initiatives
Epidemiology

4. Global Dementia Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Dementia Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
MAO Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Cholinesterase Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Glutamate Inhibitor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Dementia Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 20230
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global Dementia Drugs Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa